CD274 and kidney cancer: Post-hoc analyses of pivotal clinical trials for first-line metastatic kidney cancer included immunotherapy efficacy in tumors with sarcomatoid features. About 5-20% of advanced kidney cancers harbor sarcomatoid differentiation, the most clinically aggressive phenotype. Current studies have shown that RCC with sarcomatoid features may express even higher levels of PD-L1.